Literature DB >> 3942721

Cytolytic activity of liposomes containing stearylamine.

E Yoshihara, T Nakae.   

Abstract

In order to develop the cytotoxic liposome, the cytolytic effect of polycationic liposome was examined. Upon incubation of the stearylamine-containing liposome (stearylamine-liposome) with rabbit erythrocyte, a significant extent of hemolysis was observed. Hemolytic activity of the liposome depends on the amount of stearylamine in the liposome membrane. The plots of the initial rate of hemolysis versus the concentration of stearylamine-liposome showed a sigmoidal curve, suggesting that stearylamine-liposomes act cooperatively on the erythrocyte membrane. Hemolytic activity of stearylamine-liposome was markedly influenced by the composition of hydrocarbon chains of the phospholipids in the liposome membrane, suggesting that the membrane fluidity of stearylamine-liposome is important to evoke the hemolysis. Since the liposomes containing acidic phospholipids inhibited markedly the stearylamine-liposome-caused hemolysis, it is likely that the primary target of stearylamine-liposome is the negatively charged component(s) such as acidic phospholipids on the erythrocyte membrane. Furthermore, stearylamine-liposome induced the release of the intravesicular contents from the liposome made of acidic phospholipids but not from the liposome made of phosphatidylcholine only. These results suggest that stearylamine-liposome interacted with the negative charges of the erythrocyte membrane and eventually damaged the cell. Erythrocytes from rabbit, horse and guinea pig are highly susceptible to stearylamine-liposome but those from man, sheep, cow and chicken are less so.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3942721     DOI: 10.1016/0005-2736(86)90068-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.

Authors:  George Mattheolabakis; Ting Nie; Panayiotis P Constantinides; Basil Rigas
Journal:  Pharm Res       Date:  2011-11-10       Impact factor: 4.200

2.  In vitro-in vivo myotoxicity of intramuscular liposomal formulations.

Authors:  S A al-Suwayeh; I R Tebbett; D Wielbo; G A Brazeau
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

3.  In vitro lysis of the bloodstream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes.

Authors:  H Tachibana; E Yoshihara; Y Kaneda; T Nakae
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  Comparison of cell proliferation and toxicity assays using two cationic liposomes.

Authors:  K Lappalainen; I Jääskeläinen; K Syrjänen; A Urtti; S Syrjänen
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

5.  Interaction of liposome-associated all-trans-retinoic acid with squamous carcinoma cells.

Authors:  R Parthasarathy; P G Sacks; D Harris; H Brock; K Mehta
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria.

Authors:  Vinoth Rajendran; Shilpa Rohra; Mohsin Raza; Gulam Mustafa Hasan; Suparna Dutt; Prahlad C Ghosh
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

7.  A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes.

Authors:  Manjarika De; Sneha Ghosh; Triparna Sen; Md Shadab; Indranil Banerjee; Santanu Basu; Nahid Ali
Journal:  Mol Ther Nucleic Acids       Date:  2017-11-01       Impact factor: 8.886

Review 8.  Liposome-polymer complex for drug delivery system and vaccine stabilization.

Authors:  Abd Kakhar Umar; Nasrul Wathoni; James H Zothantluanga; Sanjoy Das; Jittima Amie Luckanagul
Journal:  Heliyon       Date:  2022-02-12

Review 9.  Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems.

Authors:  Eliana B Souto; João Dias-Ferreira; Sara A Craveiro; Patrícia Severino; Elena Sanchez-Lopez; Maria L Garcia; Amélia M Silva; Selma B Souto; Sheefali Mahant
Journal:  Pathogens       Date:  2019-08-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.